|
Resolution: standard / high Figure 4.
The Bax:Bcl-2 ratio measured by Western blot analysis. Four treatment groups: control (CTL); 40 μM dexamethasone (DXM) for 8 h; 100 μM temozolomide (TMZ) for 6 h; pretreatment with 40 μM DXM for 2 h followed by 100 μM TMZ for 6 h. (A) A representative gel picture showing level of expression of Bax. (B) A representative gel picture showing level of expression of Bcl-2. (C) A representative gel picture showing level of expression of β-actin. (D) Densitometric analysis showing the Bax:Bcl-2 ratio in all treatment groups. Significant difference between CTL and TMZ treated cells was indicated by * (P ≤ 0.05) and significant difference between TMZ treated cells and DXM plus TMZ treated cells was indicated by # (P ≤ 0.05).
Das et al. Molecular Cancer 2004 3:36 doi:10.1186/1476-4598-3-36 |